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Ginseng is widely used for its promising healing and restorative properties as well as for its possible tonic
effect in traditional medicine. Nowadays, many studies focus on puriﬁed individual ginsenoside, an
important constituent in ginseng, and study its speciﬁc mechanism of action instead of whole-plant
extracts on cardiovascular diseases (CVDs). Of the various ginsenosides, puriﬁed ginsenosides such as
Rb1, Rg1, Rg3, Rh1, Re, and Rd are the most frequently studied. Although there are many reports on the
molecular mechanisms and medical applications of ginsenosides in the treatment of CVDs, many con-
cerns exist in their application. This review discusses current works on the countless pharmacological
functions and the potential beneﬁts of ginseng in the area of CVDs. Results: Both in vitro and in vivo
results indicate that ginseng has potentially positive effects on heart disease through its various prop-
erties including antioxidation, reduced platelet adhesion, vasomotor regulation, improving lipid proﬁles,
and inﬂuencing various ion channels. To date, approximately 40 ginsenosides have been identiﬁed, and
each has a different mechanism of action owing to the differences in chemical structure. This review aims
to present comprehensive information on the traditional uses, phytochemistry, and pharmacology of
ginseng, especially in the control of hypertension and cardiovascular function. In addition, the review
also provides an insight into the opportunities for future research and development on the biological
activities of ginseng.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Cardiovascular disease (CVD) is the leading cause of death
globally. According to the World Health Organization, CVD was
responsible for 30% of all deaths in 2005. Although typically
considered a disease of developed countries, its incidence is
increasing in the developing world as well. CVD usually stems from
vascular dysfunction, for example, as a result of atherosclerosis,
thrombosis, or high blood pressure, which then compromises or-
gan function. Most notably, the heart and brain can be affected, as
in myocardial infarction and stroke, respectively. In the past few
decades, major improvements have been made in treating some
types of CVD. However, new treatment options are urgently neededPhysiology, College of Veterinary
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e Korean Society of Ginseng, Publfor all types of CVD. Moreover, improving diagnosis is crucial,
because by detecting the early stages of disease, the focus of ther-
apy could be shifted from treatment to prevention [1]. CVD is the
leading cause of morbidity and mortality in millions of people
around the world, which include a variety of diseases such as pe-
ripheral vascular disease, coronary artery disease, heart failure,
dyslipidemias, and hypertension [2]. People of all races, age, and
gender suffer commonly from these diseases. Heart failure,
myocardial rupture, or arrhythmia is a result of myocardial necrosis
following infarction [3]. Myocardial infarction and sudden death
continue to remain as one of the leading causes of morbidity and
mortality in many countries, despite vast advances in the past ﬁve
decades. In addition, risk factors such as cigarette smoking,Medicine, Biosafety Research Institute, Chonbuk National University, 664-14, 1ga,
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density lipoprotein cholesterol, diabetesmellitus, and hypertension
are the primary causes of CVD [4]. Recent studies elucidate that
vascular inﬂammation may also manifest in atherosclerosis and
coronary artery disease [5]. Endothelial dysfunction has been
stimulated by risk factors involved in CVD, such as expression of
adhesion molecules by these dysfunctional endothelial cells, which
promote the binding and inﬂux of T cells and mast cells [6]. An
inﬂammatory condition within the arterial wall is created by in-
terleukins, cytokines, and reactive oxygen species (ROS) produced
by white blood cells. Low-density lipoprotein is an atherogenic li-
poprotein that accesses the subendothelial space and undergoes
oxidative modiﬁcationwhen trapped in the intercellular matrix [7].
Panax ginseng is a traditional herbalmedicine that has been used
therapeutically for more than 2000 years. It is the most valuable of
all medicinal plants, especially in Korea, China, and Japan. The
name panax means “all healing,” and has possibly stemmed from
traditional belief that the various properties of ginseng can heal all
aspects of the illness encountered by the human body (i.e., it acts as
a panacea for the human body). Among the ginseng species, Korean
ginseng (P. ginseng), Chinese ginseng (Panax notoginseng), and
American ginseng (Panax quinquefolius) are the most common
throughout the world. Numerous studies focus on the research of
individual ginsenosides instead of using whole ginseng extract
against various diseases [8e13]. Of the various ginsenosides, Rb1,
Rg1, Rg3, Re, and Rd are the most frequently studied [13].
This review describes the medicinal potentials of using ginseng
and ginsenosides in the treatment of CVD. The review explores
recent studies carried out to understand the mechanisms that lead
to various diseases and discusses the implications of these ad-
vances for identifying new therapeutic targets and developing new
therapeutic strategies, including the potential use of ginseng and its
metabolite (i.e., ginsenosides) for treating CVD.
2. Efﬁcacy of ginseng in improving circulation and
antioxidant activity
Ginseng and ginsenosides have vasorelaxation, antioxidative,
anti-inﬂammatory, and anticancer properties. In addition, ginseno-
sides have also shown to have an effect on the nervous system [14].
Moreover, ginseng has shown more beneﬁt in individuals with dis-
eases compared with healthy individuals [15e17]. In addition, a
previous study supported its growing evidence for its indications in
CVDs [12]. P. ginseng roots and extracts have been traditionally used
by Koreans to renew the body and mind, and improve physical con-
dition. Ginseng is alsowidely used in individuals with cardiovascular
risk factors such as hypertension and hypercholesterolemia. Cardiac
ischemia can cause myocardial injury that leads to the production of
ROS, and in such cases, treatment with ginseng restores coronary
blood ﬂow to normal levels [18]. Alteration or loss of cellular function
results innonspeciﬁc damage to lipids, proteins, andDNAbyROS. The
life span of animals bearing a tumor has gradually increased after
ginseng treatment [19]. Oxidation-induced damage of erythrocyte
membrane was reduced by ginsenosides Rg2 and Rh1 [20], and the
energy metabolism and protection of the mitochondria have been
effectively regulated by polysaccharides from P. ginseng [21]. Facili-
tation of antioxidant effect through Nrf2 and levels of antioxidant
enzymes such as superoxide dismutase and glutathione peroxidase
were signiﬁcantly increased by ginseng [22,23].
Ginsenosides protect from myocardial reperfusion injury by
increasing 6-keto-prostaglandin F1a production and decreasing
lipid peroxidation [24]. Rabbit pulmonary endothelium was pro-
tected from ROS toxicity by ginsenosides [8]. In addition, ginseng
prevented ROS toxicity by stimulating nitric oxide (NO) production.
Endothelial dysfunction was induced by homocysteine and humanimmunodeﬁciency virus protease inhibitors; however, these were
successfully blocked by ginsenoside Rb1 and other ginsenosides by
inhibiting the production of ROS [25,26]. Ginsenoside Re is a potent
antioxidant that protects cardiomyocytes against oxidant-mediated
injury. Such protection is, at least in part, mediated by its radical
scavenging properties, especially for H2O2 and hydroxyl radicals. As a
major constituent in ginseng extract, ginsenoside Re may play an
important role in antioxidant actions to increase cardiomyocyte
survival and contractile function during ischemia and reperfusion
[27,28]. These results suggest that ginsenoside Re functions as an
antioxidant, protecting cardiomyocytes from oxidant injury induced
by both exogenous and endogenous oxidants, and that its protective
effects may be mostly attributed to scavenging H2O2 and hydroxyl
radicals.
3. Efﬁcacy of ginseng in modulating vascular function
Interestingly, when glucose is attached to the 20th carbon of
dammarane triterpene, such as ginsenosides Re, Rd, and R1, the
ginsenosides acted as an antioxidant. By contrast, if no sugar moi-
eties were attached to the 20th carbon of the ginsenosides such as
Rg3, Rh2, and Rg2, the ginsenosides acted as a prooxidant. In gin-
senosides such as Rh1, glucose is attached to the sixth carbon
instead of the 20th, and in this case, the ginsenoside acts as an
antioxidant only [29]. All these aggregated reports revealed that the
prevention of ROS generation by ginseng may be an important
milestone in the prevention of oxidative damage. Ginsenoside Rb1
has protective effects on human umbilical vein endothelial cells in
vitro [30]. Water extract of Korean red ginseng stimulates angio-
genesis by activating the phosphoinositol-3-kinase (PI3K)/Akt-
dependent extracellular signal-regulated kinase 1/2 and endothe-
lial nitric oxide synthase (eNOS) pathways in human umbilical vein
endothelial cells [31]. Angiomodulatory and neurological effects are
also shown by ginsenosides [32]. One study shows that potassium
channels of vascular smooth muscle cells have been activated by
ginsensoside Re through the PI3K/Akt and NO pathways [33].
Another study shows that ginsenoside Re has nongenomic effects
in endothelial cells through the glucocorticoid receptor (GR) [34].
Capillary morphogenesis was attenuated by ginsenoside Rb1 [35].
Another in vitro study revealed the enhancement of vascular
endothelial cell proliferation and migration by extracts of P. ginseng
and P. notoginseng [36]. Saponin from P. notoginseng shows angio-
genic effects on both human umbilical vein endothelial cells and in
zebraﬁshmodels [37]. It is also reported that atherosclerotic lesions
in apolipoprotein E (ApoE)-deﬁcient mice and tumor necrosis fac-
tor-alpha-induced endothelial adhesion molecule expression have
been reduced by P. notoginseng [38]. Production of NO was
increased by ginsenoside Rg3 by increasing phosphorylation and
expression of eNOS [39]. In human umbilical vein endothelial cells,
ﬁbroblast growth factor-induced angiogenesis was inhibited by
compound K through the modulation of p38 mitogen-activated
protein kinase (PK) and Akt [40]. The aforementioned reports
propose that the saponin extracted from ginseng protects vascular
endothelial cells through the NO-, Akt-, and GR-mediated signaling
pathways. Effects of ginseng and ginsenosides have been sufﬁ-
ciently studied on the cardiovascular system. Through the pro-
duction and release of NO, endothelium regulates blood vessel tone
[41e43]. Production of NO has been stimulated by ginsenosides by
a number of ways. It is reported that NO production in human aortic
endothelial cells was induced by puriﬁed ginsenoside Rb1 [44].
Ginsenoside stimulates NO release in human umbilical vein endo-
thelial cells by phosphorylation of GR, PI3K, Akt/PKB, and eNOS
[45]. In isolated canine corpus cavernosummodel, ginsenoside Rg3
induced vasodilation [46], which shows that arterial stiffness has
been improved by Korean red ginseng and ginsenosides [47].
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Vascular smooth muscle dysfunction and the inhibition of
angiotensin II-induced proliferation were stimulated by ginseno-
side Rg3 [48,49]. In addition, Korean red ginseng improves arterial
stiffness in hypertension [50]. Overall, these results show the
improvement in vasomotor function by ginseng. It has initially
been thought that ginseng may increase blood pressure to
harmful levels. However, previous studies have shown that
ginseng cures patients with low blood pressure, restoring it to
normal levels. In addition, ginseng also reduces blood pressure in
patients with high blood pressure [51]. The blood pressure
lowering activity of Korean ginseng is attributed to the production
of vascular endothelial cell-derived NO [52]. Recent studies have
shown that ginseng has biochemical and pharmacological activ-
ities beneﬁcial for blood pressure control, where lower doses have
greater antihypertensive effects than higher doses [53], and
improve blood circulation through vasodilation [52]. The antihy-
pertensive effect of ginseng is mediated by the inhibition of
myogenic responses on the blood vessels [54]. In addition, ginseng
protects against tissue damage and is also a novel therapy for
heart failure [55].
5. Efﬁcacy of ginseng in improving cardiac functions
Saponins from P. notoginseng protected the heart against doxo-
rubicin-induced cardiotoxicity [56] and blocked the cardiac hy-
pertrophy induced by monocrotaline in rats [57]. Left ventricular
hypertrophy produced by aortic coarctation was protected by gin-
senoside Rg1 through NO functions [58]. Electromechanical alter-
nans was suppressed by ginsenoside Re in cardiomyocytes [59], and
myocardial infarction after ischemia and reperfusion was pre-
conditionally protected by ginsenoside Rb1 [60]. Another study
showed that ginsenoside Rg1 inhibits left ventricular hypertrophy
[61]. P. ginseng also suppresses apoptosis in neonatal cardiocytes by
modulating Bcl-2 and caspase-3 activities during hypoxia and
reperfusion [62]. Furthermore, cardiomyocytes have been pro-
tected by ginsenoside Rg1 from oxidative injury through anti-
oxidation and intracellular calcium modulation [63]. Total saponin,
panaxadiol, and panaxatriol from ginseng have been able to protect
cardiomyocytes from ischemia and reperfusion injuries [64]. Car-
diac injury in diabetes induced by streptozotocin has been pre-
vented by ginsenoside Rb1 [65] and unfavorable postmyocardial
remodeling was reduced by ginseng [66]. Some studies suggest that
cardiac hypertrophy and heart failure are prevented by ginseng
through Nhe-1 modulation and reduction of calcineurin activation
[67]. Recent studies also show that cardiac protection by NO was
facilitated by compound K through the Akt/PI3K pathway [68].
Acute cardiac injury from ischemia and reperfusion has been pro-
tected through the GR and estrogen receptor-activated risk
pathway by the eNOS-dependent mechanism in rats [69]. Thus,
these studies suggest that ginseng preserves heart function after
myocardial tissue deterioration.
6. Efﬁcacy of ginseng in inhibiting platelet aggregation
Increasing evidence proves the ability of ginseng to inhibit
platelet aggregation. The red ginseng has a direct inhibitory effect
on platelet aggregation in in vivo antithrombotic and ex vivo an-
tiplatelet models, and this could correlate with its ability to in-
crease NO production. It has been reported that the saponin
fraction of Korean red ginseng enhances the formation of citrul-
line from exogenously added arginine, which activates NOS, and
puriﬁed ginsenosides from ginseng enhanced the release of NO
from endothelial cells of the rat aorta. Korean red ginseng alsoshows a signiﬁcant protective effect on arterial thrombosis in vivo,
which may be due to antiplatelet activity rather than anti-
coagulation activity, and this result suggests that red ginseng
intake may be beneﬁcial for individuals with high risks of
thrombosis and CVDs [70e72]. Dihydroginsenoside Rg3 potently
inhibited platelet aggregation through the modulation of down-
stream signaling components such as cyclic adenosine mono-
phosphate and extracellular signal-regulated kinase 2 [73].
Protopanaxadiol or protopanaxatriol-type ginsenosides have a
complicated effect on hemin-induced hemolysis, which depends
on the interaction between the sugar moieties at different posi-
tions [74].
Post-treatment with P. notoginseng signiﬁcantly reduced the
lipopolysaccharide-mediated microcirculatory disturbance by
inhibiting adherence of leukocytes to the venular wall, degran-
ulation of mast cells, and the release of cytokines [75]. A total of
seven ginsenosides, namely Rg6, F4, Rk3, Rh4, Rs3, Rs4, and Rs5,
isolated from processed ginseng were evaluated for their effects
on platelet aggregation induced by adenosine diphosphate
(ADP), collagen, arachidonic acid, and U46619 (thromboxane A2
mimetic drug). The acetylated ginsenosides such as Rs3, Rs4, and
Rs5 only had mild effects on aggregation induced by four
stimulators. Some of the ginsenosides including Rg6, F4, Rh4,
Rs3, and Rs5 showed negligible effects on ADP and collagen-
induced platelet aggregation [76]. There are some synergistic
interactions between Korean red ginseng and warfarin in
patients with cardiac valve replacement. Korean red ginseng
could be used with close monitoring and under appropriate
instruction in patients who take warfarin during cardiac valve
replacement. Because such patients could take higher amounts
of Korean red ginseng along with warfarin, this combination can
also be applied in cardiac valve treatment [77]. Coronary
perfusion ﬂow of isolated heart can be increased by total gin-
senosides, which also protected heart tissues from ischemia/
reperfusion injury. This effect of total ginsenosides is mediated
by activation of PI3K/Akt-eNOS signaling and NO production
[78]. These results suggest that ginseng has a potent antith-
rombotic effect in vivo, which may be due to the antiplatelet
activity rather than the anticoagulation activity, and that
ginseng intake may be beneﬁcial for individuals with high risks
of thrombosis and CVDs.
7. Efﬁcacy of ginseng in adjusting lipid proﬁle
Patients with myocardial ischemia showed an improvement in
coronary ﬂow following treatment with red ginseng extract [79].
Thus, this result shows that blood circulation was signiﬁcantly
improved by the anticoagulant properties of ginseng. It is well-
known that the hypolipidemic and hypoglycemic effects of
red ginseng were dramatically increased by the biﬁdus fermen-
tation process [80]. Although hypercholesterolemia increases
platelet aggregation, using Korean red ginseng reduces the ag-
gregation through the suppression of diacylglycerol liberation in
a high-cholesterol diet [81]. Saponins from P. notoginseng
decrease atherosclerosis by regulating the lipid with its anti-in-
ﬂammatory effects [82], and total Panax notoginsenosides was
reported to inhibit atherosclerosis in ApoE-knockout mice [83].
In foam cells, cholesterol ester can be reduced by saponins from
P. notoginseng by modulating the adenosine triphosphate-binding
cassette transporter A1 [84]; in addition, acidic polysaccharides
from Korean red ginseng were also reported to possess anti-
hyperlipidemic activity [85]. Atherosclerosis in ApoE-knockout
mice was inhibited by the action of ginsenoside Rd [86] as
well. These ﬁndings suggest the antihyperlipidemic effect of
P. ginseng.
Fig. 1. Pathogenesis of hypercontracture after cardiac ischemia/reperfusion during the overload of sodium and calcium. ATP, adenosine triphosphate.
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Previous studies have shown that ginsenoside Rd treatment
attenuates basilar hypertrophic inward remodeling in 2k2c hyper-
tensive rats without affecting systemic blood pressure. Ginsenoside
Rd reversed the increase in store-operated Ca2þ channel (SOCC) or
receptor-operated Ca2þ channel (ROCC) but not in voltage-depen-
dent Ca2þ channelemediated Ca2þ entry. In vitro, ginsenoside Rd
concentration dependently inhibited endothelin-1-induced basilar
arterial vascular smooth muscle cells (BAVSMCs) proliferation and
Mn2þ quenching rate within the same concentration range as
required for inhibition of increased SOCC- or ROCC-mediated Ca2þ
entries during hypertension. These results provide in vivo evidence
for attenuation of hypertensive cerebrovascular remodeling after
ginsenoside Rd treatment. The underlying mechanism might be
associated with inhibitory effects of ginsenoside Rd on voltage-
independent Ca2þ entry and BAVSMC proliferation [87]. Intracel-
lular Ca2þ is the central regulator of cardiac contractility. Moreover,
it is becoming increasingly apparent that alterations in myocyte
Ca2þ regulation may be critically important in both the mechanical
dysfunction and arrhythmogenesis associated with congestive
heart failure. Thus, it is imperative to have a clear and relatively
quantitative understanding of how cellular Ca2þ levels are regu-
lated during the normal contractionerelaxation cycle. During the
cardiac action potential, L-type Ca2þ channels are activated and
Ca2þ enters the cell through Ca2þ current (ICa); a much smaller
amount of Ca2þ also enters by NaþeCa2þ exchange (NCX). The Ca2þ
inﬂux triggers Ca2þ release from the sarcoplasmic reticulum (SR)
and, to some extent, can also directly contribute to activation of the
myoﬁlaments. The Ca2þ entry along with the amount released from
the SR through the Ca2þ-induced Ca2þ release increases cytosolic-
free [Ca2þ] ([Ca2þ]i), resulting in the binding of Ca2þ to multiple
cytosolic Ca2þ buffers. One of the most functionally important
cytosolic Ca2þ buffers is the thin-ﬁlament protein troponin C (TnC).
When Ca2þ binds to TnC, it switches on the myoﬁlaments in a
cooperative manner, thereby activating contraction. For relaxation
and diastolic ﬁlling to occur, [Ca2þ]i must decline such that Ca2þ
dissociates from TnC, thereby turning off the contractile machinery.The following four Ca2þ transporters remove Ca2þ from the cytosol:
(1) SR Ca2þeadenosine triphosphatase (Ca2þeATPase), (2) sarco-
lemmal NCX, (3) sarcolemmal Ca2þeATPase, and (4) mitochondrial
Ca2þ uniporter. The SR Ca2þeATPase and NCX are the most
important quantitatively [88]. Because cardiac functions are carried
out by the calcium ions [Ca2þ], these are crucial for the modulation
of intracellular calcium signaling. Intracellular Ca2þ levels are
tightly regulated by the Ca2þ-activated signaling pathways (Fig. 1).
Ginsenosides with sugar moieties attached only to the C-3 po-
sition of the steroid-like structure, equivalent to the sugar position
in cardiac glycosides, have an inhibitory effect on Naþ/KþeATPase
activity. However, their inhibitory potency was signiﬁcantly
reduced when a monosaccharide was linked to the C-6 or C-20
position of the steroid-like structure; replacement of the mono-
saccharide with a disaccharide molecule at either position caused
the disappearance of the inhibitory potency. Molecular modeling
and docking conﬁrmed that the difference in Naþ/KþeATPase
inhibitory potency among ginsenosides was due to the steric hin-
drance of sugar attachment at the C-6 and C-20 positions of the
steroid-like structure. The cardiac therapeutic effects of ginseng
and San Qi should be at least partly attributed to the effective in-
hibition of Naþ/KþeATPase by their metabolized ginsenosides with
sugar moieties attached only to the C-3 position of the steroid-like
structure [89].
9. Concluding remarks
This review summarized current information about the efﬁ-
cacy of ginseng on major cardiovascular risk factors such as hy-
pertension, cardiac disease, hyperlipidemia, oxidative stress, and
ion regulation. Ginseng is a traditional herbal remedy whose
antiquity stretches back to ancient times. The active constituent
ginsenosides play a vital role in the medicinal effects of ginseng.
Ginsenosides exhibit their vast range of activities on CVD through
the inhibition of ROS production, stimulation of NO production,
improvement in blood circulation, enhancement of vasomotor
tone, and regulation of the lipid proﬁle. However, the exact
mechanisms of action of ginsenosides are still unidentiﬁed. In the
C.H. Lee and J.-H. Kim / Effect of Ginseng on Cardiovascular Diseases 165future, each ginsenoside must be studied on its speciﬁc mecha-
nism of action on CVD. The common use of ginseng as an herbal
remedy requires strict investigations to assess both its efﬁcacy
and its safety.Conﬂicts of interest
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